Idiopathic Hypersomnia

SomnusNooze Articles > Hypersomnias > Idiopathic Hypersomnia


Act Today and Let Your Voice Be Heard

Very recently, the Hypersomnia Foundation became aware of an opportunity to help shape the future of sleep research. The National Institutes of Health, the primary source of funding for medical research in the United States, has issued a Request for Information, which you can view at: https://grants.nih.gov/grants/guide/notice-files/NOT-HL-16-312.html. The final date to...

Continue Reading

Sleep-Wake Disturbance Following a Traumatic Brain Injury

Background According to the Centers for Disease Control and Prevention (CDC), more than 2 million people in the United States suffer a traumatic brain injury (TBI) every year. Most people with a TBI will also experience a sleep-wake disturbance (a real or perceived change in night-time sleep with resulting daytime...

Continue Reading

What Does One SOREMP Mean?

Background The primary feature of the two main central disorders of hypersomnolence—narcolepsy and idiopathic hypersomnia (IH)—is excessive daytime sleepiness, defined in the International Classification of Sleep Disorders, third edition, as “daily episodes of an irrepressible need to sleep or daytime lapses into sleep." Overnight sleep testing (polysomnography) and a...

Continue Reading

A Comparison of Sodium Oxybate in the Treatment of Idiopathic Hypersomnia and Narcolepsy Type 1

Background Sodium oxybate (SXB) is a drug sold as Xyrem in the United States by Jazz Pharmaceuticals, in Europe by UCB Pharma, and in Canada by Valeant Pharmaceuticals. It is approved in the United States in adults for the treatment of excessive daytime sleepiness (EDS) and...

Continue Reading

Does Excessive Daytime Sleepiness Affect Children’s Pedestrian Safety?

Background Each year, approximately 30,000 children are unintentionally killed or injured while walking outside (typically within a half mile of their homes). Many factors—including children’s thinking and reasoning abilities, attention spans, reaction times, impulsiveness, and willingness to take risks—likely play a role. Excessive daytime sleepiness (EDS),...

Continue Reading

The Hypersomnia Foundation Welcomes New Board Members

We are pleased to announce that Scot Hulshizer, Celia King, and Diane Powell have recently been elected to the Board of Directors of the Hypersomnia Foundation. In addition to bringing unique strengths as the organization thrives and grows in both scope and depth, each new Board...

Continue Reading

Raising Awareness of the Underpinnings of Hypersomnia

Awareness of disease means different things to different people. One’s awareness takes origin in experiences and goals, both personal and professional. Diversity in awareness therefore comprises our community of people who have hypersomnia, their significant others, healthcare professionals, and research scientists. People who have hypersomnia need...

Continue Reading

Antibiotic May Decrease EDS in GABA-Related Hypersomnia

A study of clarithromycin in the treatment of GABA-related hypersomnia indicates that this drug may be effective in some patients with idiopathic hypersomnia (IH), narcolepsy without cataplexy, and subjective hypersomnia. Background The US Food and Drug Administration (FDA) has not approved any drugs for the treatment of IH....

Continue Reading

It’s a Fine Line Between Type 2 Narcolepsy and Idiopathic Hypersomnia… and It’s Getting Even Finer

Researchers have provided more evidence that narcolepsy without cataplexy (Nw/oC ) and idiopathic hypersomnia (IH) without long sleep time (LST) look more alike on testing than do narcolepsy with cataplexy (NwC) and Nw/oC. This research was completed before the publication of the International Classification of Sleep Disorders...

Continue Reading

Get SomnusNooze, our e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive and email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!